GeoVax's GEO-MVA Vaccine Receives EMA Backing, Streamlining Path to Market Amid Global Mpox Concerns

The European Medicines Agency (EMA) has provided GeoVax Labs, Inc. with positive Scientific Advice for its GEO-MVA vaccine, a significant step forward in the fight against Mpox and smallpox. This guidance confirms that a single Phase 3 immuno-bridging trial could suffice for evaluating the vaccine's efficacy and supporting a Marketing Authorization Application (MAA) in Europe. This development is crucial as it simplifies the regulatory pathway, potentially speeding up the availability of an additional vaccine option amidst growing concerns over Mpox outbreaks worldwide.

The EMA's Committee for Medicinal Products for Human Use (CHMP) agreed with GeoVax's proposed non-clinical studies and immunogenicity endpoints, which are designed to demonstrate the vaccine's non-inferiority to the currently approved MVA vaccine, Imvanex. This agreement eliminates the need for Phase 1 and Phase 2 trials, marking a significant reduction in the time and resources typically required for vaccine development. GeoVax's CEO, David Dodd, highlighted the importance of this milestone, noting the urgent need for diversified vaccine supplies as the World Health Organization continues to declare Mpox a Public Health Emergency of International Concern.

The global health landscape is currently reliant on a single supplier for MVA-based Mpox and smallpox vaccines, making the potential approval of GEO-MVA a critical development for global health resilience. The emergence of highly virulent strains of Mpox and its detection in wastewater across multiple U.S. states underscore the pressing need for expanded vaccine availability. GeoVax's progress with GEO-MVA, coupled with its next-generation manufacturing capabilities, positions the company as a key player in addressing both immediate and long-term vaccine needs.

GeoVax's initiative to shift to its next-generation AGE1 manufacturing platform is expected to enhance production scalability and cost-effectiveness, particularly in regions like Africa where vaccine self-sufficiency is a priority. The company's commitment to working with global regulators aims to ensure broad access to GEO-MVA, reinforcing the importance of manufacturing resilience and transparency in the face of escalating Mpox transmission and strained vaccine stockpiles.

This regulatory advancement comes at a pivotal moment, as public health authorities worldwide grapple with the challenges of Mpox outbreaks and the need for effective, accessible vaccines. The EMA's endorsement of GeoVax's development strategy for GEO-MVA not only accelerates the potential approval timeline but also represents a significant step toward strengthening global preparedness against Mpox and smallpox.